Physician profile
James Chandler
NPI 1447350152
$7,437.40
in general payments reported to CMS, 2019-2025
34 companies · $765 in 2025
The $765 reported for 2025 was more than what 85% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $165 · 2020: $186 · 2021: $707 · 2022: $2,766 · 2023: $611 · 2024: $2,238 · 2025: $765.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,530 · Travel and Lodging: $1,076 · Gift: $8.74.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,529.57 |
| Travel and Lodging | $1,075.56 |
| Gift | $8.74 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tela Bio, INC. | $2,031.22 | 2019-2025 | Ovitex Reinforced Bioscaffold With Permanent Polymer (Ovitex) |
| Intuitive Surgical, INC. | $1,870.92 | 2022-2025 | |
| Davol INC. | $714.01 | 2021-2025 | Phasix Mesh |
| Abbvie INC. | $636.91 | 2021-2025 | Dalvance, Strattice Reconstructive Tissue Matrix Bps |
| Allergan, INC. | $329.50 | 2019-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $258.89 | 2020-2025 | Gattex |
| Medtronic, INC. | $255.55 | 2022-2025 | Symbotex, Signia, Aquamantys(Tm) |
| Myriad Genetic Laboratories, INC. | $254.65 | 2021-2025 | Myrisk |
| Csl Behring | $139.18 | 2019-2021 | |
| Hologic Sales and Service, LLC | $118.91 | 2023-2025 | Coolseal Generator, Biozorb, Localizer |
| Ethicon US, LLC | $91.73 | 2020-2025 | Harmonic |
| Smith+Nephew, INC. | $75.48 | 2022-2025 | Collagenase Santyl |
| Vertex Pharmaceuticals Incorporated | $68.80 | 2024-2025 | |
| Molli Surgical (US) INC | $62.38 | 2024 | |
| Hydrofera LLC | $53.28 | 2025 | Hydrofera Blue |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Shire North American Group INC | $52.74 | 2019 | |
| Integra Lifesciences Corporation | $49.63 | 2022-2023 | Integra, Integra Dermal Regeneration Template, Omnigraft |
| Sanara Medtech INC. | $34.27 | 2022-2023 | Celleraterx |
| Carl Zeiss Meditec, INC. | $32.22 | 2019 | |
| Pacira Pharmaceuticals Incorporated | $31.05 | 2022-2025 | Exparel |
| Innovation Technologies INC | $30.82 | 2024 | Irrisept |
| Tetraphase Pharmaceuticals, INC. | $30.46 | 2020 | |
| Heron Therapeutics, INC. | $28.30 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $27.57 | 2024 | Lynparza, Keytruda |
| Conmed Corporation | $24.89 | 2024 | Airseal |
| Innocoll Pharmaceuticals Limited | $20.44 | 2022 | |
| Enterra Medical, INC. | $18.78 | 2022 | |
| Trevena, INC. | $18.26 | 2022 | |
| Misonix INC | $16.04 | 2020 | |
| Hologic INC | $14.92 | 2022 | |
| Zimmer Biomet Holdings, INC. | $14.02 | 2024 | Ribfix Blu Advantage |
| Coopersurgical, INC. | $13.57 | 2025 | Onetrac Lx |
| Somavac Medical Solutions, INC. | $13.10 | 2021 | |
| Bolder Surgical LLC | $4.91 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Chandler listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.